Alvotech (ALVO) announced that the FDA has completed the reinspection of the company’s Iceland facility that started earlier this month. Alvotech received a form 483 with one observation after the regulatory body’s reinspection. Previously, certain deficiencies were found at the Iceland facility. Based on this, Alvotech remains confident about receiving approval for its two biosimilar candidates, AVT02 and AVT04, in the United States by Feb 24, 2024 and Apr 16, 2024, respectively. Shares of the company were ...